药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02268 药明合联

未开盘 09-08 16:08:36

74.700

+2.150

+2.96%

最高76.550	最低71.600	成交量599.95万
今开73.950	昨收72.550	日振幅6.82%
总市值947.20亿	流通市值947.20亿	总股本12.68亿
成交额4.49亿	换手率0.47%	流通股本12.68亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02268","market":"HK","secType":"STK","nameCN":"药明合联","latestPrice":74.7,"timestamp":1788854916003,"preClose":72.55,"halted":0,"volume":5999503,"delay":0,"changeRate":0.029634734665747838,"floatShares":1268000000,"shares":1268000000,"eps":1.119999,"marketStatus":"未开盘","change":2.15,"latestTime":"09-08 16:08:36","open":73.95,"high":76.55,"low":71.6,"amount":449133207,"amplitude":0.068229,"askPrice":74.7,"askSize":11500,"bidPrice":74.65,"bidSize":9500,"shortable":3,"etf":0,"ttmEps":1.393408732,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788917400000},"marketStatusCode":0,"adr":0,"listingDate":1700150400000,"exchange":"SEHK","adjPreClose":72.55,"openAndCloseTimeList":[[1788831000000,1788840000000],[1788843600000,1788854400000]],"volumeRatio":0.8645287137059455,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02268","defaultTab":"news","newsList":[{"id":"1108386564","title":"异动解读｜药明合联盘中上涨3.17%，报74.85港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1108386564","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108386564?lang=zh_cn&edition=full","pubTime":"2026-09-08 13:13","pubTimestamp":1788844416,"startTime":"0","endTime":"0","summary":"9月8日，药明合联盘中上涨3.17%，报74.85港元/股，成交额1.18亿港元。药明合联所在的生命科学工具和服务行业中，个股普遍走强，其中英矽智能涨9.11%，金斯瑞生物科技涨9.03%，晶泰控股涨0.77%，药明康德涨0.73%，药明生物涨0.58%。药明合联生物技术有限公司是一家主要从事抗体偶联药物（ADC）及其他生物偶联药物的全面合同研究、开发及制造组织（CRDMO）服务的投资控股公司，主要在国内市场、北美、欧洲和世界其他地区市场开展业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665398249","title":"【券商聚焦】中信建投：上半年收入与利润双增，医药行业步入新发展周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2665398249","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665398249?lang=zh_cn&edition=full","pubTime":"2026-09-07 09:04","pubTimestamp":1788743053,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，2026年上半年医药行业整体收入与扣非净利润实现双增长，创新药、CXO、制药装备及科学试剂等板块积极复苏，行业步入新发展周期。创新药收入+58.68%，扭亏为盈，出海总金额超900亿美元，全年有望超越2025年水平，国际化持续兑现；CXO收入+25.2%，扣非净利润+66.5%，订单旺盛，上行周期确立。随着集采出清、创新放量、出海落地及上游国产化提升，行业有望开启高质量发展周期，龙头将持续受益。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990791","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01789","02367","BK1585","LU2488822045.USD","LU1720050803.USD","BK1191","02228","KURE","LU0228659784.USD","LU0417516902.SGD","BK1161","LU2778985437.USD","BK1500","KCE","06821","BK1141","BK1593","601066","01099","09688","06160","IE00B5MMRT66.SGD","SG9999004311.SGD","LU2476274308.USD","IE00B3M56506.USD","LU0828237510.HKD","LU1770034418.SGD","LU2476274720.SGD","BK1197","LU0348825331.USD","01530","LU2399975544.HKD","02268","BK1207","BK1100","HK0000165453.HKD","BK1588","02196","BK1574","LU1969619763.USD","03933","09926","LU0348827113.USD","LU2328871848.SGD","LU0640798160.USD","BK1515","LU1115378108.SGD","BK1583","IE00BPRC5H50.USD","LU0588546209.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137510605","title":"药明合联更新2026年8月股份变动月报，已发行股份增至1,268,295,784股","url":"https://stock-news.laohu8.com/highlight/detail?id=1137510605","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137510605?lang=zh_cn&edition=full","pubTime":"2026-09-04 18:06","pubTimestamp":1788516368,"startTime":"0","endTime":"0","summary":"药明合联于2026年9月4日发布了截至2026年8月31日的股份变动月报表。报告显示，截至期末，公司法定/注册股本维持稳定，总额为500,000美元，面值为每股0.00005美元，法定/注册股本数量仍为10,000,000,000股，较上月无变化。已发行股份方面，月初为1,266,466,942股，期内因多项购股权行权增发1,828,842股，期末已发行股份总数升至1,268,295,784股。截至8月底，公司已确认满足16.47%的最低公众持股量要求，股本整体保持增至1,268,295,784股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175342620","title":"药明合联：药明康德（上海）医药研发有限公司减持，好仓比例降至14.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=1175342620","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175342620?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:50","pubTimestamp":1788515457,"startTime":"0","endTime":"0","summary":"药明康德（上海）医药研发有限公司于2026年8月31日以每股均价73.23港元卖出药明合联5352.40万股，涉资约39.20亿港元。药明康德（上海）医药研发有限公司此次减持前持有药明合联好仓2.33亿股，占比18.36%；减持后持股量为1.79亿股，好仓比例降至14.14%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111182224","title":"药明合联：STA Pharmaceutical Hong Kong Investment Limited (合全药业香港投资有限公司)减持，好仓比例降至14.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=1111182224","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111182224?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:41","pubTimestamp":1788514913,"startTime":"0","endTime":"0","summary":"STA Pharmaceutical Hong Kong Investment Limited (合全药业香港投资有限公司)于2026年8月31日以每股均价73.23港元卖出药明合联股份5352.40万股，涉资约39.20亿港元。STA Pharmaceutical Hong Kong Investment Limited (合全药业香港投资有限公司)此次减持前持有药明合联好仓2.33亿股，占比18.36%；减持后持股量为1.79亿股，好仓比例降至14.14%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194505613","title":"药明合联：WuXi AppTech Co., Ltd. (无锡药明康德新药开发股份有限公司)减持，好仓比例降至14.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=1194505613","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194505613?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:17","pubTimestamp":1788513437,"startTime":"0","endTime":"0","summary":"无锡药明康德新药开发股份有限公司于2026年8月31日以每股均价73.23港元卖出药明合联股份5352.40万股，涉资约39.20亿港元。无锡药明康德新药开发股份有限公司此次减持前持有药明合联好仓2.33亿股，占比18.36%；减持后持股量为1.79亿股，好仓比例降至14.14%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136892164","title":"药明合联：上海合全药业股份有限公司减持，好仓比例降至14.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=1136892164","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136892164?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:12","pubTimestamp":1788513120,"startTime":"0","endTime":"0","summary":"上海合全药业股份有限公司于2026年8月31日以每股均价73.23港元卖出药明合联股份5352.40万股，涉资约39.20亿港元。上海合全药业股份有限公司此次减持前持有药明合联好仓2.33亿股，占比18.36%；减持后持股量为1.79亿股，好仓比例降至14.14%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664338902","title":"大摩：在药明合联H股的持股比例降至2.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664338902","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664338902?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:09","pubTimestamp":1788512983,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1141","SG9999014674.SGD","LU2488822045.USD","02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664238859","title":"【券商聚焦】交银国际：医药行业收入稳健增长 多重利好推动盈利表现显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2664238859","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664238859?lang=zh_cn&edition=full","pubTime":"2026-09-04 09:00","pubTimestamp":1788483634,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，1H26港股/A股医药行业整体收入增长4.7%/3.2%。创新药产业链增速领跑行业，服务板块复苏：1）港股/A股CXO收入整体增长29.2%/25.3%，（扣非）净利润增长23.4%/67.6%，在各子板块中增速最快，行业整体景气度和订单需求处于高位。2）核心成药板块收入增长17.8%/3.4%、利润增长62.7%/35.0%。其中生物药增速远超化药，在板块收入中的占比也进一步提升。3）医院、器械、诊断、疫苗等板块业绩有复苏趋势。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990646","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","IE00B0JY6N72.USD","01951","KURE","09926","LU0315179316.USD","01276","LU0039217434.USD","03329","06160","02269","03759","LU1242518857.USD","HK0000320264.USD","01952","HK0000306685.HKD","02162","LU0327786744.USD","02268","BK1161","BK1589","01530","02596","BK1515","01093","06821","IE00B543WZ88.USD","LU0588546209.SGD","09966","BK1209","SG9999004220.SGD","06990","03692","LU0307460666.USD","02096","LU1251922891.USD","06996","KCE","LU2543165471.USD","LU1880383366.USD","LU0348783233.USD","IE00B5MMRT66.SGD","01177","06078","02273","LU1152091168.USD","LU0856984785.SGD","09996","01548","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163285032","title":"异动解读｜药明合联盘中上涨3.59%，机构回补增持叠加连跌后技术性反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1163285032","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163285032?lang=zh_cn&edition=full","pubTime":"2026-09-03 09:48","pubTimestamp":1788400087,"startTime":"0","endTime":"0","summary":"9月3日，药明合联盘中上涨3.59%，报73.65港元，成交额7833.97万港元，为此前连续多日回落后的明显反弹。消息面上，联交所最新权益披露显示，Schroders PLC于8月31日以每股均价71.01港元增持药明合联51.65万股，涉资约3667.90万港元，持股比例由4.99%回升至5.03%。前期受大股东药明康德大额减持约39.20亿港元影响，股价从逾80港元高位连续回落至70港元附近，短期抛压消化后叠加机构回补，推动今日反弹。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明合联获机构回补增持，股价止跌反弹","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199259113","title":"药明合联：Schroders PLC增持，好仓比例升至5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=1199259113","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199259113?lang=zh_cn&edition=full","pubTime":"2026-09-02 17:14","pubTimestamp":1788340468,"startTime":"0","endTime":"0","summary":"Schroders PLC于2026年8月31日以每股均价71.0146港元买入药明合联股份51.65万股，涉资约3667.90万港元。Schroders PLC此次增持前持有药明合联好仓6326.85万股，占比4.99%；增持后持股量为6378.50万股，好仓比例升至5.03%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664850558","title":"药明合联(02268.HK)遭Schroders PLC减持53.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664850558","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664850558?lang=zh_cn&edition=full","pubTime":"2026-09-01 23:07","pubTimestamp":1788275227,"startTime":"0","endTime":"0","summary":"格隆汇9月1日丨根据联交所最新权益披露资料显示，2026年8月28日，药明合联(02268.HK)遭Schroders PLC在场内以每股均价73.0378港元减持53.1万股，涉资约3878.3万港元。\r\n\r\n　　减持后，Schroders PLC最新持股数目为6326.85万股，持股比例由5.04%下降至4.99%。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/01/20260901913091.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/01/20260901913091.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260901/32357056.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU2488822045.USD","BK1141","02268","SG9999014674.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100956662","title":"药明合联：Schroders PLC减持，好仓比例降至4.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=1100956662","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100956662?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:23","pubTimestamp":1788168210,"startTime":"0","endTime":"0","summary":"Schroders PLC于2026年8月28日以每股均价73.0378港元卖出药明合联股份53.10万股，涉资约3878.31万港元。Schroders PLC此次减持前持有药明合联好仓6379.95万股，占比5.04%；减持后持股量为6326.85万股，好仓比例降至4.99%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120209189","title":"异动解读｜药明合联盘中下跌3.27%，药明康德第五次大额减持叠加机构减仓持续施压","url":"https://stock-news.laohu8.com/highlight/detail?id=1120209189","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120209189?lang=zh_cn&edition=full","pubTime":"2026-08-31 09:57","pubTimestamp":1788141426,"startTime":"0","endTime":"0","summary":"8月31日，药明合联盘中下跌3.27%，报71.0港元，成交额1.52亿港元，为中报绩后飙升逾13%以来连续多个交易日回落。消息面上，药明康德于8月26日通过大宗交易出售药明合联5352.4万股，约占总股本4.23%，套现约39.20亿港元，为其自2024年11月以来第五次减持，累计回笼资金约108.70亿港元。同日，Schroders PLC亦以每股均价77.29港元减持249.4万股，持股比例由5.05%降至4.86%。大股东与机构资金集中抛售，叠加短期涨幅过大后的获利回吐压力，持续对股价形成压制。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"药明康德第五次大额减持，药明合联承压下跌","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663442960","title":"药明合联(02268.HK)遭Schroders PLC减持249.4万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2663442960","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663442960?lang=zh_cn&edition=full","pubTime":"2026-08-30 22:27","pubTimestamp":1788100023,"startTime":"0","endTime":"0","summary":"格隆汇8月30日丨根据联交所最新权益披露资料显示，2026年8月26日，药明合联(02268.HK)遭Schroders PLC在场内以每股均价77.2902港元减持249.4万股，涉资约1.93亿港元。\r\n\r\n　　减持后，Schroders PLC最新持股数目为6151.85万股，持股比例由5.05%下降至4.86%。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202608/30/20260830130833.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202608/30/20260830130833.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260830/32353855.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02268","LU2488822045.USD","SG9999014674.SGD","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663017005","title":"每周股票复盘：药明康德（603259）出售药明合联获31.43亿税前收益","url":"https://stock-news.laohu8.com/highlight/detail?id=2663017005","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663017005?lang=zh_cn&edition=full","pubTime":"2026-08-30 01:12","pubTimestamp":1788023528,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，药明康德报收于157.4元，较上周的162.86元下跌3.35%。本周，药明康德8月24日盘中最高价报163.4元。来自公司公告汇总：药明康德因可转债转换新增发13,631,632股H股。交易信息汇总8月27日药明康德发生一笔3828.48万元的大宗交易。药明康德于2026年8月26日通过大宗交易出售间接持有的药明合联53,524,000股股票，约占其总股本的4.23%，成交金额约39.20亿港元，预计产生税前投资收益约31.43亿元，占公司2025年度经审计归母净利润超10%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000000373.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","LU1046422090.SGD","LU1997244956.HKD","LU0052750758.USD","LU1251922891.USD","LU1719994722.HKD","LU0320764599.SGD","LU2242644610.SGD","LU1969619763.USD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU0700851271.USD","LU1934453819.USD","LU0469268626.HKD","LU2495084118.USD","LU0348766576.USD","LU0708995583.HKD","LU2045819591.USD","LU1770034418.SGD","LU1979443071.USD","LU1997245094.SGD","SG9999014674.SGD","LU2328871848.SGD","BK1583","BK0216","02268","LU0611395673.USD","603259","LU0327786744.USD","LU2488822045.USD","LU2125910500.SGD","02359","LU0456842615.SGD","LU1808992512.USD","IE00BPRC5H50.USD","LU0572944931.SGD","LU0348767384.USD","LU1997245177.USD","LU1303224171.USD","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187097699","title":"药明合联：8月28日合计发行1,707,842股普通股，涉资约610.08万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1187097699","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187097699?lang=zh_cn&edition=full","pubTime":"2026-08-28 21:18","pubTimestamp":1787923133,"startTime":"0","endTime":"0","summary":"药明合联（港交所：02268）于2026年8月28日公告，公司在2026年8月25日至8月28日期间，依据2021年及2023年首次公开发售前购股权计划，多次发行新股合计1,707,842股，占发行前已发行股份总数（1,266,466,942股）约0.13%。本次发行价格区间介乎每股1.8024港元至7.501港元，合计涉资约610.08万港元。\n本次发行完成后，公司的已发行股本增至1,268,174,784股，库藏股数为0。公司确认已获董事会正式授权，并在所有相关程序中遵守了香港上市规则及相关法律法规。本公告由执行董事兼首席财务官席晓捷签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药明合联：8月28日合计发行1,707,842股普通股，涉资约610.08万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126355221","title":"异动解读｜药明合联盘中下跌3.18%，药明康德第五次大宗减持套现约39亿港元加剧抛压","url":"https://stock-news.laohu8.com/highlight/detail?id=1126355221","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126355221?lang=zh_cn&edition=full","pubTime":"2026-08-28 10:17","pubTimestamp":1787883451,"startTime":"0","endTime":"0","summary":"8月28日，药明合联盘中下跌3.18%，报73.1港元，成交额2.44亿港元，为绩后飙升逾13%以来连续第三个交易日回落。消息面上，药明康德8月27日晚公告，于8月26日通过大宗交易出售药明合联5352.4万股，约占总股本4.23%，成交金额约39.20亿港元，预计影响2026年税前利润约31.43亿元。这是药明康德自2024年11月以来第五次减持药明合联，累计回笼资金约108.70亿港元。药明康德表示所得资金将用于聚焦CRDMO主业及全球产能建设。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"药明康德高位减持套现39亿港元，药明合联承压下跌","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662839520","title":"药明康德(02359.HK)通过大宗交易出售药明合联5352.4万股股票 套现约39.2亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662839520","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662839520?lang=zh_cn&edition=full","pubTime":"2026-08-27 21:46","pubTimestamp":1787838371,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["SG9999014674.SGD","LU0348767384.USD","02268","BK1141","02359","LU1046422090.SGD","LU2242644610.SGD","LU0052750758.USD","LU2125910500.SGD","BK1583","LU0327786744.USD","LU2045819591.USD","LU0708995583.HKD","LU0348766576.USD","LU0469268626.HKD","LU0572944931.SGD","LU2488822045.USD","BK1576","LU0320764599.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662703695","title":"药明康德：出售药明合联股票资产 预计影响2026年税前利润约31.43亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662703695","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662703695?lang=zh_cn&edition=full","pubTime":"2026-08-27 18:13","pubTimestamp":1787825619,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1576","LU0469268626.HKD","LU2495084118.USD","LU1719994722.HKD","LU2328871848.SGD","IE00B5MMRT66.SGD","LU0320764599.SGD","LU1934453819.USD","BK1141","LU2045819591.USD","LU1808992512.USD","IE00B543WZ88.USD","LU0611395673.USD","LU1046422090.SGD","LU1997245177.USD","LU0456842615.SGD","LU0327786744.USD","LU2242644610.SGD","603259","LU2125910500.SGD","BK0216","LU0572944931.SGD","BK1583","LU1997245094.SGD","LU0348767384.USD","LU0700851271.USD","LU1969619763.USD","IE00BPRC5H50.USD","02268","LU1251922891.USD","LU1303224171.USD","LU0708995583.HKD","LU1979443071.USD","LU2488822045.USD","LU1770034418.SGD","SG9999014674.SGD","02359","LU0052750758.USD","LU0348766576.USD","LU1997244956.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://wuxixdc.com","stockEarnings":[{"period":"1week","weight":0.0484},{"period":"1month","weight":0.2058},{"period":"3month","weight":0.6099},{"period":"6month","weight":0.3472},{"period":"1year","weight":0.1067},{"period":"ytd","weight":0.2296}],"compareEarnings":[{"period":"1week","weight":-0.0005},{"period":"1month","weight":-0.0137},{"period":"3month","weight":0.0373},{"period":"6month","weight":-0.0155},{"period":"1year","weight":-0.0124},{"period":"ytd","weight":-0.0122}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"药明合联生物技术有限公司是一家主要从事提供提供抗体偶联药物（ADC）及其他生物偶联药物的全面合同研究、开发及制造组织（CRDMO）服务的投资控股公司。该公司的服务包括生物偶联药物、单克隆抗体中间体及生物偶联药物相关连接子及有效载荷的发现、工艺开发及优良生产质量管理规范（GMP）生产。该公司透过按有偿服务（FFS）基准的合约和按全时当量（FTE）基准的合约向客户提供CRDMO服务。该公司主要在国内市场、北美、欧洲和世界其他地区市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.222222,"avgChangeRate":0.010265},{"month":2,"riseRate":0.666667,"avgChangeRate":0.058284},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.010372},{"month":4,"riseRate":0.555556,"avgChangeRate":0.03555},{"month":5,"riseRate":0.333333,"avgChangeRate":0.006014},{"month":6,"riseRate":0.4,"avgChangeRate":-0.032735},{"month":7,"riseRate":0.4,"avgChangeRate":0.011785},{"month":8,"riseRate":0.4,"avgChangeRate":-0.114063},{"month":9,"riseRate":0.333333,"avgChangeRate":0.019767},{"month":10,"riseRate":0.777778,"avgChangeRate":0.151657},{"month":11,"riseRate":0.333333,"avgChangeRate":0.008796},{"month":12,"riseRate":0.111111,"avgChangeRate":-0.068876}],"exchange":"SEHK","name":"药明合联","nameEN":"WUXI XDC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药明合联,02268,药明合联股票,药明合联股票老虎,药明合联股票老虎国际,药明合联行情,药明合联股票行情,药明合联股价,药明合联股市,药明合联股票价格,药明合联股票交易,药明合联股票购买,药明合联股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}